PIK3CA and Miyoshi myopathy: In clinical trials for MM, the response rate (RR) of monotherapy with PD-1 inhibitors is only approximately 23.5%, partly attributed to the immunosuppressive state caused by persistent activation of the PI3K-AKT pathway (74).